Peptide Week in 5 minutes: telehealth reaches for the brand-name bottle, and USP names what's missing (November 2 to 8, 2026)

By · Published · 6 min read · 19 sources, 18 checked at the source

A rainy window seat with a closed laptop, a cup of coffee on a saucer and a gray knitted blanket in soft overcast light.

Two telehealth companies announced deals this week to sell Lilly's FDA-approved GLP-1 medicines at Lilly's own cash price. Meanwhile the group that writes America's drug-quality rulebooks said HHS's six-peptide policy is missing the standards a pharmacist would test against. No law or FDA list changed. Plenty else did.

Facts are as of November 8, 2026. Sources, with retrieval dates, are at the bottom.

What changed for you this week

  • If you get a GLP-1 through a telehealth app, more of them can now send the brand-name medicine, at the manufacturer's self-pay price, instead of a compounded version. [V]
  • The comment window on HHS's six-peptide policy closes at 11:59 PM Eastern this Friday, November 13. Regulations.gov showed 115 posted comments this morning. [V]
  • USP said none of the six peptides has an official quality standard yet. That's a statement, not a rule change. [V]
  • FDA's compounding lists, its 503BSection of federal drug law for outsourcing facilities: larger compounders that register with FDA and must follow drug-manufacturing quality rules. Glossary entry page and its advisory-committee page didn't move. [V]

The week, day by day

  • Tuesday, Nov 3. The U.S. Pharmacopeia (USP) said the HHS policy "does not include essential safeguards" for quality, because the six peptides have no USP–NF monographs, reference standards or official names. [V] More in our USP explainer and monograph primer.
  • Wednesday, Nov 4. Novo Nordisk's nine-month report says it's preparing for a U.S. CagriSema launch in early 2027, "subject to regulatory approval." [V] (Our CagriSema piece.) The same day, the ad industry's watchdog, NAD, told a telehealth seller to drop "personalized" claims for its compounded tirzepatide after a Lilly challenge. [V] (Our NAD write-up.)
  • Thursday, Nov 5. LifeMD said its affiliated mail-order pharmacy can now fill and ship Zepbound and Foundayo at Lilly's self-pay price, cash only, not billed to insurance. [V] (Our LifeMD brief.)
  • Friday, Nov 6. Lilly and Hims & Hers announced a similar agreement for the same two medicines. [V] Novo also released two real-world Wegovy studies in MASH, which it describes as retrospective and observational. [V] We covered the Lilly–Hims deal, the liver data and how much weight real-world evidence carries.
  • Weekend. No FDA Federal Register notice on compounding, the 503B list or peptides. [V] We published a melanotan II evidence page and a SAFE Drugs Act guide.

“Hims & Hers has never offered access to compounded copies of Lilly's GLP-1s, and has committed not to do so in the future.”

Lilly and Hims & Hers, November 6, 2026

What the two telehealth deals add up to

For a long stretch, the telehealth GLP-1 story was about compounded copies and how they were marketed; FDA's 30 warning letters in March were about exactly that. This week two platforms put the branded medicine inside their own checkout instead. [V] The compounding rules didn't change. What changed is that an FDA-approved option now sits inside more of the apps people already use, at a published self-pay price. [V]

The Hims & Hers half drew double-takes, since FDA named the company in its February 2026 statement on compounded GLP-1 marketing. [V] The release says nothing about Hims & Hers' compounded-peptide offerings or the FTC's lawsuit against it. [V]

Where the cornerstone timeline stands

On our regulation timeline, no line changed status this week. The interim six-peptide policy is still published and in force, with comments open until November 13. [V] FDA's 503ASection of federal drug law covering compounding by state-licensed pharmacies and doctors, usually for a prescription written for one patient. Glossary entry bulks page still reads content current as of 05/14/2026, and its 503B bulks page 01/07/2025. [V] The compounding advisory committee page still says only that a meeting will happen before the end of February 2027, with melanotan II among the five substances listed. [V] USP's statement isn't a regulator's decision, and USP says so itself. [V]

Still waiting on

  1. The comment close, Friday, November 13 (10:59 PM Central). After that, FDA has to decide what to do with the record in its 503A rulemaking. No proposed rule has appeared. [V] (How the comment period works.)
  2. A final 503B decision on semaglutide, tirzepatide and liraglutide. Nothing in the Federal Register this week. [V]
  3. A date for FDA's next compounding advisory meeting. Still none. [V] (Our agenda preview.)
  4. The SAFE Drugs Act (S.3794). Still on the Senate calendar, where it has sat since July 27; no floor vote. [V]
  5. FTC v. Hims & Hers. A court-docket aggregator shows the hearing on Hims & Hers' motion to dismiss reset to January 14, 2027. [S] We haven't opened the court's own docket for that change.

On the calendar for November 9 to 15

  • Today, Sunday, Nov 8: an ESSENCE post hoc analysis of semaglutide in MASH patients with a BMI under 27 is listed in Novo's program for an 11:45–12:00 oral session at the Denver meeting. [V] Novo calls post hoc analyses hypothesis-generating. [V] If results come out, we'll add them to our ESSENCE explainer.
  • Monday, Nov 9: Hims & Hers reports third-quarter results after the market closes, with a call at 5:00 PM Eastern. [V] Listen for anything on the Lilly deal or its peptide plans.
  • Friday, Nov 13: the HHS docket closes; a final tally update of the comment count follows.

Peptide Policy Watch

Peptide Week in 5 minutes: telehealth reaches for the brand-name bottle, and USP names what's missing (November 2 to 8, 2026)

Published November 8, 2026 · https://peptidepolicywatch.com/2026/11/08/weekly-telehealth-brand-name-glp1-usp-peptide-quality/

Printable checklist

Questions to bring to your next telehealth visit

Questions this page raises, worth bringing to a clinician or pharmacist familiar with your health history.

  1. Is the medicine you'd prescribe the FDA-approved brand or a compounded version, and how would I tell from the label?
  2. Is the price a self-pay price from the manufacturer, and does it go through insurance at all?
  3. Which pharmacy fills it, and what state is it licensed in?

Print view Select it, then use your browser’s Print command to print only this box.

Watching

  1. Q1 2027Retatrutide: Lilly still says it plans to submit retatrutide for U.S. approval in Q1 2027, and FDA's GLP-1 page says it can't be compounded and that research-labeled versions are unapproved drugs. No change this week (Lilly release July 23, 2026; FDA page current as of October 1, 2026; both re-opened November 8). [V]

What this week does and doesn't mean

A telehealth app offering a brand-name GLP-1 isn't an FDA endorsement of the app, and it doesn't change what the law says about compounded copies. It's a business arrangement for approved medicines at a cash price. And USP's verdict doesn't pull the six peptides from the HHS policy, which stays in force until rulemaking settles them or HHS revisits it. [V] Both stories circle the same question: who sets the quality bar, and who gets to sell what's on the label.

Sources (retrieved November 8, 2026 unless noted)

  1. U.S. Pharmacopeia, "USP statement on quality and safety considerations for unapproved peptides," November 3, 2026 [V] — https://www.usp.org/news/usp-statement-on-quality-and-safety-considerations-for-unapproved-peptides
  2. Novo Nordisk, financial report for the first nine months of 2026, GlobeNewswire, November 4, 2026 [V] — https://www.globenewswire.com/news-release/2026/11/04/3395015/0/en/novo-raises-full-year-outlook-on-continued-glp-1-momentum-with-third-quarter-adjusted-operating-profit-increasing-27-at-cer-to-dkk-31-720-million.html
  3. BBB National Programs, NAD decision on Good Life Meds compounded tirzepatide claims, November 4, 2026 [V] — https://bbbprograms.org/media/newsroom/decisions/good-life
  4. LifeMD, Inc., release on Lilly self-pay GLP-1 medicines, GlobeNewswire, November 5, 2026 [V] — https://www.globenewswire.com/news-release/2026/11/05/3396309/0/en/lifemd-expands-access-to-lilly-s-self-pay-glp-1-medicines-enabling-option-to-dispense-and-ship-directly-to-patients-nationwide.html
  5. Eli Lilly and Hims & Hers, "Lilly and Hims & Hers expand access to FDA-approved Lilly medicines," PR Newswire, November 6, 2026 [V] — https://www.prnewswire.com/news-releases/lilly-and-hims--hers-expand-access-to-fda-approved-lilly-medicines-302931979.html
  6. Novo Nordisk, real-world Wegovy MASH studies release, PR Newswire, November 6, 2026 [V] — https://www.prnewswire.com/news-releases/novo-real-world-studies-link-wegovy-2-4-mg-to-reductions-in-liver-enzymes-weight-and-blood-sugar-in-adults-with-mash-at-the-liver-meeting-aasld-2026--302932360.html
  7. Novo Nordisk US, AASLD The Liver Meeting 2026 program release, October 28, 2026 (oral presentation 0072, November 8, 11:45–12:00) [V] — https://www.novonordisk-us.com/media/press-releases/novo-nordisk-mash-liver-data-aasld-2026.html
  8. Hims & Hers, "Hims & Hers to Announce Third Quarter 2026 Financial Results on November 9, 2026," October 12, 2026 [V] — https://investors.hims.com/news/news-details/2026/Hims--Hers-to-Announce-Third-Quarter-2026-Financial-Results-on-November-9-2026/default.aspx
  9. Regulations.gov public data service, docket HHS-OASH-2026-0496: 115 comments posted, document 0001 open for comment until 11:59 PM Eastern, November 13, checked 10:06 AM CT [V] — https://www.regulations.gov/docket/HHS-OASH-2026-0496
  10. Federal Register, 91 FR 68526 (FR Doc. 2026-22192), October 30, 2026 [V] — https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances
  11. Federal Register API searches of FDA documents published since November 2, 2026 ("compounding," "503B," "peptide," "bulk drug substances") [V] — https://www.federalregister.gov/api/v1/documents.json
  12. FDA, 503A bulks page, content current as of 05/14/2026 [V] — https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
  13. FDA, 503B bulks page, content current as of 01/07/2025 [V] — https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act
  14. FDA, Pharmacy Compounding Advisory Committee meeting page, content current as of 04/15/2026 [V] — https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee
  15. FDA, "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss," content current as of 10/01/2026 [V] — https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  16. FDA, "FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs," February 6, 2026 (retrieved November 7, 2026) [V] — https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs
  17. Congress.gov API, S.3794 actions (latest: placed on Senate Legislative Calendar, Calendar No. 524, July 27, 2026) [V] — https://www.congress.gov/bill/119th-congress/senate-bill/3794/all-actions
  18. Eli Lilly, TRIUMPH-2 and TRIUMPH-3 release, July 23, 2026 [V] — https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional
  19. DocketBird (secondary; court-docket aggregator), FTC et al. v. Hims & Hers Health, Inc., N.D. Cal. 3:26-cv-07871 [S] — https://www.docketbird.com/court-cases/Federal-Trade-Commission-et-al-v-Hims-Hers-Health-Inc/cand-3:2026-cv-07871
Cite or link to this page

Peptide Policy Watch staff. “Peptide Week in 5 minutes: telehealth reaches for the brand-name bottle, and USP names what's missing (November 2 to 8, 2026).” Peptide Policy Watch. Published November 8, 2026. https://peptidepolicywatch.com/2026/11/08/weekly-telehealth-brand-name-glp1-usp-peptide-quality/

Link: https://peptidepolicywatch.com/2026/11/08/weekly-telehealth-brand-name-glp1-usp-peptide-quality/

Spot a mistake? See how we source and our corrections policy.

Image: AI-generated. Image credits